Although there is credible evidence on the adverse impact of overexpression of osteopontin on muscle regeneration [23], while hypoxia and inflammation could also trigger its expression [25], this is the first study describing the involvement of osteopontin in limiting myofibre adaptation in atrophic patients with COPD. The gene discussed is SPP1; the disease is chronic obstructive pulmonary disease.